Skip to main content
Medical Reference · Condition Monograph

Chronic Lymphocytic Leukemia

만성림프성백혈병

A blood cancer in which mature lymphocytes proliferate slowly; it is often discovered incidentally during health checkups without symptoms. Depending on the degree of progression, observation or targeted therapy is chosen.

History

Chronic lymphocytic leukemia (CLL) is known as a disease in which “mature-looking lymphocytes” slowly accumulate in the blood, bone marrow, and lymph nodes. In the past, it was described only at the level of grouping together patients whose white blood cell counts became abnormally high when their blood was examined under a microscope, but as blood testing technology and immunology advanced, it became possible to distinguish “which type of lymphocyte is increasing.”

In the late 20th century, as technologies that read markers on the surface of cells in the blood, such as flow cytometry, became established in clinical practice, CLL could be distinguished more accurately from other lymphomas and acute leukemias. Later, as fluorescence in situ hybridization (FISH), a test that looks for chromosomal abnormalities, and molecular tests that identify gene mutations came into wide use, it became clear that “even within the same CLL, the pace and response differ from patient to patient.”

Treatment has also changed greatly. In the past, cytotoxic chemotherapy was central, and the treatment goal was often closer to “reducing the white blood cell count.” Recently, with the arrival of targeted therapies that block signals important to cancer cell survival, treatment options have broadened. In particular, as drugs such as Bruton tyrosine kinase (BTK) inhibitors and BCL-2 inhibitors have made “long-lasting, well-tolerated treatment” possible, CLL has increasingly taken on the character of a long-term managed disease in many patients.

Causes

In most cases, “a single cause” of CLL cannot be identified. It is not a disease that is caught from someone like a cold or that arises because of one particular food. Instead, it is safer to understand it as a condition whose risk rises when several factors overlap.

One of the most widely known risk factors is family history. If a first-degree relative has had CLL or a similar lymphoid tumor, the likelihood of developing it may be higher than in people without such a history. However, having a family history does not mean CLL will necessarily develop, and many patients have no family history at all.

Exposure to certain chemicals is mentioned as an environmental factor, but it is difficult to conclude at the individual level that “CLL developed because of this exposure.” In addition, CLL generally tends to develop over a long period, so it is hard to explain by a single short-term event.

In summary, CLL is usually a disease in which “small cellular changes accumulated over a long time” push certain lymphocytes toward multiplying without being able to control themselves. Genetic predisposition, age, the immune environment, and chance genetic changes are thought to act together in this.

Genetic Epidemiology

Rather than being a hereditary disease (a disease caused by a single gene defect determined from birth), CLL is closer to a condition in which heredity partly influences “an individual's constitution and level of risk.” In other words, heredity may be involved, but it is not explained in the form of simple Mendelian inheritance, “passed down directly from parent to child.”

The observation that CLL develops more often in people with a family history suggests that several gene variants can combine to raise the risk. These variants are largely distinguished from “changes that appear only in cancer cells after the cancer develops” (acquired changes). Acquired changes are often not present in all the cells of the patient's body but are concentrated only in the population of CLL cells.

What is considered especially important in clinical practice is that the genetic features of the CLL cells affect prognosis and treatment choice. Typically, findings such as TP53 abnormalities or del(17p) can change the treatment strategy. In addition, the mutation status of the immunoglobulin heavy-chain variable region gene (IGHV) is known to be associated with the rate of disease progression. It is helpful to understand “genetic epidemiology” on two levels: the tendency for the disease to occur within families, and the fact that the genetic features of the cancer cells after diagnosis determine the direction of treatment.

General Epidemiology

CLL tends to be found more commonly mainly from middle age onward. It can occur at younger ages as well, but in general the risk increases with age. By sex, it is known to be relatively more common in men.

There are also reports of differences in incidence by region and race. However, these differences may be influenced not only by genetic background but also by differences in health checkup culture, access to diagnosis, and health care systems. For example, because many cases are discovered incidentally by blood tests while still asymptomatic, “how often blood tests are done” can affect the statistics.

Because CLL often progresses slowly, a considerable number of patients are only observed without starting treatment immediately from the time of diagnosis. It is therefore also a disease in which the “number of diagnosed patients” and the “number of patients receiving treatment” do not match. When understanding the epidemiology of CLL, the concept of “prevalence (people currently diagnosed and under management)” is important along with “incidence (new diagnoses).”

Pathogenesis

The core of CLL is that lymphocytes of the B-cell lineage survive abnormally long and gradually accumulate. Normal lymphocytes increase when needed and then decrease once their role is done, maintaining balance. In CLL, however, a particular population of lymphocytes “does not die readily even when it should” and remains.

Both changes in the CLL cells themselves and the surrounding environment (the microenvironment in the bone marrow and lymph nodes) are involved in this process. CLL cells can exchange signals with surrounding cells and create an environment favorable to their survival. Therefore, rather than looking only at the numbers in the blood, it is important to also understand what is happening in the lymph nodes and bone marrow.

CLL is also characterized by “cancer cells interfering with normal immunity.” CLL cells look like lymphocytes on the outside, but in reality they cannot properly carry out normal antibody production and immune responses. As a result, immunoglobulins may decrease, or the person may become vulnerable to certain infections. In some patients, autoimmune phenomena also occur, which can appear as the body attacking its own red blood cells or platelets.

In summary, the fact that CLL is “a cancer in which abnormal lymphocytes with prolonged survival accumulate” rather than “a cancer that proliferates rapidly” explains the slow course of the disease and many of its clinical features.

Symptoms

The symptoms of CLL “may be absent, or may appear very gradually.” In fact, many people first learn of it from a finding of increased lymphocytes on a complete blood count (CBC) done during a health checkup or for another reason.

When symptoms develop, the most common is fatigue. Accompanying anemia, a chronic inflammatory state, poor sleep quality, and other factors can contribute to this. In addition, because immune function weakens, it can appear as colds that last a long time or as recurrent infections such as pneumonia or shingles.

Some patients may have systemic symptoms called B symptoms. Typical examples are fever of unknown cause, night sweats, and unintended weight loss. Because these symptoms can suggest that the disease has become more active or is progressing, evaluation by the medical team is important.

When the lymph nodes enlarge, lumps may be felt in the neck, armpits, or groin, or discomfort may be felt there. When the spleen enlarges, there may be bloating in the upper left abdomen or a feeling of becoming full quickly (early satiety). When platelets decrease, a bleeding tendency may appear, such as easy bruising, gum bleeding, or nosebleeds.

Signs

The “signs” that a physician confirms through examination or testing often appear before symptoms do. The most typical is a persistent increase in lymphocytes. If mature lymphocytes remain consistently high on blood tests, several causes including CLL are considered.

A common finding on physical examination is painless lymph node enlargement. The nodes are painless, feel firm, and can be found in several sites at the same time. Enlargement of the liver or spleen may also be present, and this is confirmed by palpation or imaging tests.

Cytopenias such as anemia or thrombocytopenia may also be observed on blood tests. In some cases this is explained by the space in the bone marrow being filled with CLL cells, or by autoimmune complications such as autoimmune hemolytic anemia (AIHA) or immune thrombocytopenia (ITP). Broken lymphocytes such as smudge cells may be seen on a peripheral blood smear; this is not a confirmatory finding on its own, but it is helpful in context. In addition, if a decrease in immunoglobulins is present, the risk of infection may increase, which is of great clinical significance.

Screening

There is generally no “national screening test recommended for everyone” for CLL. There are two reasons. First, CLL often progresses very slowly, so even if it is found at an asymptomatic stage, treatment may not be needed right away. Second, it is difficult to say with certainty that early detection always extends survival.

In reality, blood tests often play the role of a kind of “informal screening.” When a CBC is done at a health checkup, an increase in lymphocytes may be found incidentally and lead to further testing. In other words, rather than a “specific screening test,” abnormal findings on a routine blood test serve as the clue.

If there is a family history, or unexplained lymph node enlargement, recurrent infections, B symptoms, or the like, it is more reasonable to consult the medical team and receive the necessary tests appropriately rather than thinking of oneself as a “screening candidate.” When symptoms and signs are present, early evaluation itself becomes the most important safety measure.

Diagnosis

The starting point for diagnosing CLL is an increase in lymphocytes on the CBC and a peripheral blood smear. Ultimately, however, it must be confirmed whether “these lymphocytes are a uniform increase of cells of the same character (clonal).” The most important test for this is flow cytometry. It identifies which surface markers the lymphocytes in the blood have, confirming an immunophenotype consistent with CLL.

Once the diagnosis is confirmed, the next step is an evaluation to gauge the “pace and character” of the disease. This includes FISH to identify chromosomal abnormalities, tests for specific gene mutations (e.g., TP53), and determination of IGHV mutation status. These results can directly affect drug selection when treatment becomes necessary in the future.

To determine the extent of the disease, the lymph nodes, liver, and spleen are evaluated by physical examination, and if necessary, the size of organs and lymph nodes can be checked with ultrasound or CT. However, CT is not mandatory for all patients. A bone marrow examination is performed selectively when the diagnosis is unclear, when the cause of cytopenias needs to be evaluated, or when a baseline must be established before treatment.

Clinical staging systems such as the Rai staging system or the Binet staging system are used to classify risk and to decide whether treatment needs to start (or whether observation is possible). Diagnosis is not completed by “a single test” but by the combination of immunophenotype confirmation, genetic evaluation, and clinical staging.

Treatment

The most important principle in treating CLL is that “not every diagnosis requires immediate treatment.” If there are no symptoms, progression is slow, and there are no problems with organ function, “watchful waiting,” with observation at regular intervals, can be the standard approach.

Situations in which treatment becomes necessary are usually as follows: when B symptoms become pronounced, when enlarged lymph nodes or spleen cause discomfort in daily life, when anemia or thrombocytopenia progresses, or when the disease worsens rapidly. In such cases, the treatment strategy varies according to the patient's age, coexisting conditions, genetic features (such as TP53 abnormalities), and prior treatment history.

A major pillar of recent treatment is targeted therapy. BTK inhibitors work by blocking the signals that allow CLL cells to survive. BCL-2 inhibitors weaken “the mechanism that keeps cells from dying,” inducing the death of CLL cells. In some cases, immunotherapy such as anti-CD20 antibodies is combined. Prevention and management of infection are also an important part of treatment, and if immunoglobulins are low and infections recur, immunoglobulin replacement may be considered.

If autoimmune complications develop, immunomodulatory treatment such as steroids may be needed. In some high-risk patients or those with relapsed or refractory disease, hematopoietic stem cell transplantation (HSCT) or cell therapy may be discussed, but this is not a standard applied to all patients.

Prognosis

The prognosis of CLL varies greatly. Some people live for decades without major change, while in others it progresses relatively quickly and treatment becomes necessary. For this reason, it is helpful to understand CLL not as “a single disease” but as “a group of several subtypes that present in a similar way.”

Factors that determine prognosis include clinical stage (e.g., Rai, Binet), the presence of cytopenias, the size of the lymph nodes and spleen, the rate of progression, and genetic features. In particular, findings such as TP53 abnormalities or del17p are treated as important variables because they are associated with treatment response. IGHV mutation status also helps gauge the character of the disease.

With recent advances in targeted therapy, the disease can now be controlled for longer and more stably in many patients. However, the term “cure” is still used with caution, and in reality long-term management that keeps the possibility of relapse in mind is necessary. Not only CLL itself but also problems such as infections, autoimmune complications, and, rarely, transformation into another lymphoma can affect long-term prognosis, so regular follow-up is important.

Prevention

At present, no method of reliably preventing CLL is known. This is because its cause is not singular and it is the result of changes that occur over a long period. Therefore, it is difficult to say that CLL can be prevented by “a particular supplement” or “a particular lifestyle habit” alone.

Nevertheless, there are “strategies close to prevention” that are practically helpful. First, detecting abnormal signals early through health checkups or blood tests when necessary and having them evaluated appropriately. Second, because preventing infection is very important after diagnosis, hand hygiene, oral care, and basic vaccinations (discussed with the medical team according to the individual situation) can be helpful.

Third, during treatment or periods of weakened immune function, it is safer to reduce exposure to infection in crowded places and to seek medical care without delay if fever or symptoms of infection develop.

Because CLL is often a disease managed over the long term, maintaining overall physical health through sleep, nutrition, exercise, quitting smoking, and managing chronic conditions (diabetes, high blood pressure, etc.) greatly influences quality of life during “the period of living with the disease.” Even if CLL itself cannot be completely prevented, lifestyle management aimed at reducing complications and supporting a stable course is important.

This content is provided for general medical information only and does not replace individual diagnosis or treatment. If symptoms persist, please consult a medical professional.